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Objectives: Systemic administration of anti-tumor necrosis factor alpha (anti-TNF alpha) 
leads to an anti-inflammatory and joint protective effect in pathologies such as rheumatoid 
 arthritis, psoriasis, and Crohn’s disease. The aim of this study was to assess adherence to therapy, 
 persistence in treatment (no switches or interruptions), and consumption of care resources (drugs, 
outpatient services, hospitalizations).
Methods: We conducted an observational retrospective cohort analysis using the  administrative 
databases of five local health units. Patients filling at least one prescription for anti-TNF alpha 
between January 1, 2009 and December 31, 2011 were included and followed up for 1 year. 
Patients were defined as adherent if .80% of the follow-up period was covered by drugs 
dispensation.
Results: A total of 1,219 patients were analyzed (mean age 49.6±14.6, male 47%). Among 
enrolled patients, 36% were affected by rheumatoid arthritis, and 31% and 10% were affected by 
psoriasis and Crohn’s disease, respectively; other indications remained below these  percentages. 
Thirty-four percent of patients (420) were treated with adalimumab, 51% (615) with etanercept, 
and 15% (184) with infliximab. Among the 94% of patients who did not switch, those treated with 
infliximab had a higher rate of adherence across all indications (51% overall) when compared to 
that observed in patients treated with etanercept (27%) or adalimumab (23%). The mean annual 
nonpharmacological expenditure for each patient in analysis was €988 for adherent and €1,255 
for nonadherent patients. Infliximab was associated with the lowest cost for all indications as 
determined by the multivariate generalized linear model.
Conclusions: Patients treated with infliximab were associated with higher adherence and 
persistence in treatment and lower costs, as compared to those treated with adalimumab or 
etanercept.
Keywords: anti-TNF alpha, therapy adherence, cost of illness
Introduction
Tumor necrosis factor alpha (TNF alpha) is a proinflammatory cytokine that plays 
a pivotal role in immune-mediated inflammatory diseases (IMID) such as rheuma-
toid arthritis (RA), inflammatory bowel disease, psoriatic arthritis (PsA), psoriasis, 
and ankylosing spondylitis (AS). These chronic and debilitating diseases lead to 
a significant decrease in quality of life secondary to severe functional impairment 
and pain.1–2
These disorders have a high prevalence (about 1% worldwide)3–6 and have a sig-
nificant impact on patients and their families; in addition, IMID leads to a sizable 
burden to society due to high health care and non-health care-related costs.7 TNF-alpha 
antagonists (anti-TNF alpha) were among the first targeted immunotherapies introduced 
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on the market, and they changed radically the management of 
patients with autoimmune and inflammatory diseases.8
Currently, there are two monoclonal anti-TNF alpha 
antibodies (adalimumab and infliximab) and a soluble TNF 
receptor fusion protein (etanercept) licensed for clinical 
use in Italy.9–11 These drugs bind to soluble and membrane 
forms of TNF alpha and neutralize the pathological effects 
of this cytokine in IMIDs. Adalimumab and etanercept are 
administered subcutaneously, while infliximab is adminis-
tered as an intravenous infusion. Although all three drugs 
exert their beneficial effects through the blockade of TNF 
alpha binding to its receptor, there are differences in their 
site of action and molecular structure. These differences may 
explain the differential response to the three agents observed 
in individual patients, although there is no direct evidence 
to support this.12
Anti-TNF alpha agents have been found to be effica-
cious in clinical trial.13 The effectiveness of these drugs 
in the  clinical practice depends, however, on the patients’ 
 compliance with medication taking.14
The parameters affecting medication taking are  adherence, 
compliance, and persistence. In particular, nonadherence 
impacts on the chance of therapeutic success, delaying 
therapeutic remission and increasing disease severity. In 
patients with chronic pathologies such as RA, long-term 
treatment persistence is an important factor to evaluate the 
use of biological therapies in clinical practice.15
The impact on subsequent overall health care resource 
utilization of a therapy is determined primarily by the decrease 
in clinical effectiveness and by the relationship between loss 
of effectiveness and increased resource utilization.16,17 In 
general, poor treatment persistence has been associated with 
higher health care costs and utilization.18,19 As the main goal 
of health economic analyses is to inform and aid decisions 
for routine clinical practice, it is important to define the dif-
ferent factors in clinical trials versus (vs) real-life practice 
and measure their impact.
The objectives of this study were to assess the 
 pharmacoutilization (adherence to therapy and staying on 
treatment) and the direct health care costs (drugs, hospitaliza-
tions, outpatient services) of adult patients treated with anti-
TNF alpha agents (adalimumab, etanercept, and infliximab) 
according to the therapeutic indication.
Methods
Data source
In this study we used the administrative databases of five 
Italian local health units (LHU) in Emilia-Romagna, Lazio, 
Tuscany, Campania, and Lombardy. In Italy, each LHU has 
an information network that routinely records the volumes of 
expenditure of health care services in charge to the National 
Health System and thus dispensed free of charge to regis-
tered patients. This administrative database is complete and 
includes validated data, and it has been used in previous epi-
demiological studies.20 The Italian Ministry of Health defined 
these archives as 100% complete and 95% accurate.21
The data used in our study include territorial and hospital-
dispensed drugs, demographic, hospitalization, and outpatient 
services data. We used the Territorial Pharmacy Database that 
routinely measures the volume of expenditure generated by 
the dispensing of drugs to enrollees. The data available in 
each prescription claim include the patient’s national health 
number, the anatomical-therapeutic-chemical code of the 
drug dispensed, the number of packs dispensed, the number 
of units per pack, the dose, the unit cost per pack, and the 
prescription date. The Hospital Direct Drugs Distribution 
Registry contains the same data as the Territorial Pharmacy 
Database: the Beneficiaries’ Database, listing patient demo-
graphic characteristics (date of birth, sex, start and end of 
registration dates within LHUs registry, the date of death, 
and the exemption codes); the Hospital Discharge Database, 
which includes all hospitalization data, with the main and 
secondary discharge diagnoses codes classified according to 
the International Classification of Diseases, Ninth Revision 
(ICD-9-CM) and the diagnosis-related group code; and the 
Outpatient Services Registry, including all laboratory inves-
tigations, instrumental tests, and specialist checkups requests 
and the dates on which these were performed.
No identifiers related to patients were provided to the 
researchers. The ethics committees for the LHUs approved 
the study.
Cohort definition
This study was an observational retrospective cohort analysis. 
Patients aged $18 years who filled at least one prescription 
for anti-TNF alpha from January 1, 2009 to December 31, 
2011 were included. The date of the first prescription of anti-
TNF alpha was defined as the index date, which represents 
the enrollment date of the individual patient, who was then 
followed for 1 year. The clinical characteristics of the patients 
enrolled in this study were also investigated in the 1-year 
period before the index date.
The patients were characterized according to hospital 
admissions, outpatient visits, and prescribed drugs during the 
follow-up and the characterization periods. We identified RA 
(ICD-9-CM code 714), Crohn’s disease (ICD-9-CM code 555), 
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PsA (ICD-9-CM code 696.0), psoriasis (ICD-9-CM code 
696), AS (ICD-9-CM code 720.0) and ulcerative colitis 
(ICD-9-CM code 556) using ICD-9 codes retrieved from 
hospital admissions or exemption codes. The level of disease 
severity was measured using the MedStat Disease Staging 
Software®,22 which classifies the pathologies on the basis of 
their complications (Stage 1: no complications; Stage 2: local 
complications; Stage 3: complications to multiple sites or 
systemic complications). This methodology has been widely 
used to compare disease severity in retrospective studies 
when detailed clinical outcome data are unavailable.23 The 
presence of previous use of disease-modifying antirheumatic 
drug and presence of concomitant use of methotrexate (MTX) 
were also evaluated.
Adherence to therapy
Adherence was calculated according to the method used 
by Catalan and LeLorier24 and determined by calculating 
the proportion of days covered for which a patient had a 
supplied medication in the time interval of 12 months after 
the enrollment date, using the drug prescription databases 
as follows:
Proportion of days covered =  Total milligrams of the  
drug prescribed/defined 
daily dose
Total coverage (%) =  Sum of prescriptions coverage  
(days)/duration of the follow-up 
period (365 days) *100.
The use of defined daily doses was necessary because the 
dosage of infliximab depends on the weight of the patient and 
the administrative database does not provide this information. 
This method also allowed taking into account the induction 
period (if any). Patients were defined as adherent if .80% 
of the follow-up period was covered by drug dispensation. 
Adherence was calculated separately for each anti-TNF 
alpha treatment and for each diagnosis. The measurement 
of “staying in treatment” was calculated for naïve patients 
and those without medication switches. The interruption of 
treatment was defined as the absence of prescriptions in the 
last 3 months of observation period. Finally, we analyzed 
only the patients without medication switches.
Cost analysis
Costs are reported in Euros (€) currency. The costs for hospi-
talizations, treatments, and outpatient specialist services were 
classified as related and not related to the diseases in analysis. 
Drug costs (pharmacological) were evaluated at the moment 
of the purchase; outpatient services costs were evaluated 
according to regional tariffs. Hospitalization costs were 
determined using the diagnosis-related group tariff. Mean 
annual total health care costs were estimated for each diag-
nosis and separately for different anti-TNF alpha treatments. 
A subanalysis was performed considering two cohorts that 
were defined as patients with an anti-TNF alpha adherence 
level treatment .80% or ,80%, respectively. Total health 
care and medical (nonpharmacological) costs were compared 
between these two cohorts.
Statistical analysis
We summarized data as mean and standard deviation for 
continuous variables and as the number (percentage) of study 
participants for categorical variables. A multivariable logistic 
regression model was performed to estimate the odds ratios 
(ORs) and 95% confidence intervals (CIs) and to examine 
predictors of nonadherence to anti-TNF alpha therapy.
The model was used to identify differences in fac-
tors associated with persistence among treatment groups, 
 adjusting for covariates such as age, sex, MedStat disease 
stage, and prior medication with biologics.
Model discrimination was assessed using the 
c- statistics, while model calibration was assessed using the 
 Hosmer–Lemeshow test.
A generalized linear regression model with a gamma 
family and an identity link function were performed to 
examine the associations between total health care costs 
during the follow-up period and biologic agent, age, sex, 
MedStat  disease stage, prior medication with biologics, and 
adherence level (.80%).
To assess the linearity of the model, the Wald test 
was  performed; to assess the goodness of fit of the model, 
influence statistics and residuals were analyzed. Patients 
with missing data and/or who moved away to another LHU 
during that interval were excluded.
P values less than 0.05 were considered statistically 
significant. All analyses were performed using STATA 12.0 
(StataCorp LP, College Station, TX, USA).
Results
A total of 1,219 patients satisfied the study criteria and were 
included in the analysis. The mean patient age in the study 
was 49.6±14.6; 579 patients (47%) were male. Demographic 
and baseline clinical characteristics of the study population 
are shown in Table 1. Baseline patients affected by RA, 36%; 
31% had psoriasis, 10% had Crohn’s disease (CD), 7% had 
ClinicoEconomics and Outcomes Research 2014:6
Table 1 Demographic and baseline clinical characteristics
Number of subjects %
Beneficiaries 1,150,000
Patients with age $18: 930,000 81
Treated with anti-TnF-α 1,219 0.13
 adalimumab 420 34
 Etanercept 615 51
 Infliximab 184 15
Age of patients (mean ± standard 
deviation)
49.6±14.6
Male 579 47
Established (to biologic) 364 30
Diagnosis of patients
 Crohn’s disease 10
 Ulcerative colitis 3
 Psoriasis 31
 Psoriatic arthritis 7
 Rheumatoid arthritis 36
 Ankylosing spondylitis 3
 not available 11
Abbreviation: anti-TnF-α, anti-tumor necrosis factor-alpha.
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PsA, 3% had ulcerative colitis, and 3% had AS. The diagnosis 
was not available for 11% of patients. Thirty percent (n=364) 
of patients were already in treatment with biological drugs 
before the observational study period (established patients). 
During the study period, 420 patients (34%) were treated with 
adalimumab, 615 (51%) with etanercept, and 184 (15%) with 
infliximab (Table 1). The level of adherence to treatment for 
each anti-TNF alpha therapy and all indications are shown 
in Figure 1. Among the 94% of patients who did not switch, 
those treated with infliximab had the highest rate of adher-
ence across all indications, which was 51%, versus 27% with 
etanercept and 23% with adalimumab (Figure 1).
After adjusting for potential confounding variables, inf-
liximab proved to be a protective predictor of nonadherence 
for all indications compared with patients in the adalimumab 
and etanercept groups (OR ranged from 0.08 to 0.43). 
A multivariable logistic model of nonadherence to treatment 
is shown in Table 2. Among patients who started a first-line 
biological drug (infliximab n=303, etanercept n=437, and 
adalimumab n=115, respectively), persistence in treatment 
was 73% for infliximab, 67% for etanercept, and 64% for 
adalimumab (Figure 2).
Cost of illness
The overall mean annual total health care cost for each patient 
in analysis was of €11,120, of which nonpharmacological costs 
were €1,177 and pharmacological costs €9,943. The mean 
hospital annual cost, calculated per patient according to the 
level of adherence, progressively and significantly increased 
in an inverse relationship with the level of adherence. The 
nonpharmacological expenditure for each patient in analysis 
was €988 for adherent and €1,255 for nonadherent patients. 
After adjusting for potential confounding factors, multivariate 
analysis results indicated a total health care cost for infliximab 
for all indications lower than for adalimumab and etanercept. 
Due to small sample size, models on ulcerative colitis, PsA, 
and AS did not converge (Table 3).
Discussion
The study was based on real-world utilization data among 
patients with medical conditions for which anti-TNF alpha 
agents are approved for use in Italy; ie, RA, psoriasis, 
PsA, AS, and inflammatory bowel disease. This approach 
provided a comprehensive evaluation of the relationship 
between treatment adherence and health care costs in patients 
treated with etanercept, adalimumab, or infliximab according 
to their therapeutic indications. Treatment adherence is a 
critical issue in the management of a considerable propor-
tion of patients in anti-TNF therapy. Previous studies have 
suggested that the route and frequency of administration 
can affect patient treatment adherence, in addition to other 
reasons such as efficacy and toxicity.25–27 Unfortunately, the 
Crohn’s disease Ulcerative colitis Psoriasis Psoriatic arthritis Rheumatoid
arthritis
Ankylosing
spondylitis
Total
0%
37%
23%
50%
0%
35%
15%
24%
71%
Etanercept InfliximabAdalimumab
14%
23%
0%
26%
31%
52%
40%
17%
38%
23%
27%
51%
Figure 1 adherence with treatment.
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impact of nonadherence to anti-TNF alpha therapy can limit 
their potential benefit and may contribute to poor outcomes, 
including permanent joint and/or organ damage and increased 
utilization costs.28,29
Our study is the largest observational retrospective one 
to date and shows that patients treated with infliximab had 
a higher treatment adherence and persistence in treatment 
compared with patients treated with adalimumab and etan-
ercept in all indications.
Multiple studies have examined persistence and adherence 
among real-world patients treated with anti-TNF alpha agents 
such as etanercept, infliximab, and adalimumab14,30–32 demon-
strating that the overall treatment persistence with anti-TNF 
alpha therapies was different depending on the treatment.
A structured search of PubMed between 2001 and 2011 
conducted to identify publications assessing the treatment 
with TNF-alpha inhibitors provided data about adherence in 
CD and RA.33 Three studies showed that in CD the  adherence 
rate for infliximab (72%) was higher compared to that of 
adalimumab (55%), with a relative risk of 1.61 (95% CI: 
1.27–2.03), whereas in RA adherence to adalimumab (67%) 
was higher compared to that of infliximab (48%) and etaner-
cept (59%), with a relative risk of 1.41 (95% CI, 1.3–1.52) 
and 1.13 (95% CI, 1.10–1.18), respectively. In another com-
parative study, the RA adherence to infliximab was higher 
than with etanercept and adalimumab.33 In contrast, in a Swiss 
observational cohort of patients with RA (N=2,364) treated 
with at least one course of anti-TNF therapy from 1997 to 
2006, the discontinuation rate was significantly higher among 
patients treated with infliximab compared with those treated 
with etanercept or adalimumab.34
A recent Italian retrospective analysis estimating the 
long-term survival rate of the first anti-TNF-alpha treat-
ment in patients with psoriasis showed that patients treated 
with etanercept had a longer adherence (mean 51.4 months, 
1,565 days; P,0,001) compared with those on infliximab 
(36.8 months, 1,120 days) or adalimumab (34.7 months, 
1,056 days).35
Our data differ from those observed in the above stud-
ies, most likely because of the difference in the study design 
and the difference in data sources. Most European studies 
use registry-based databases, while US studies retrieve data 
Table 2 Multivariable logistic regression model of nonadherence to treatment
Crohn’s disease Psoriasis Rheumatoid arthritis
OR 95% CI P value OR 95% CI P value OR 95% CI P value 
Male 1.40 0.57–3.44 0.465 1.08 0.61–1.91 0.794 0.75 0.46–1.22 0.247
age 0.99 0.96–1.02 0.349 0.99 0.97–1.01 0.577 1.00 0.98–1.02 0.871
stage 1.24 0.42–3.60 0.699 * 2.31 0.99–5.40 0.052
Etanercept** 2.37 0.72–7.80 0.155 0.51 0.27–0.97 0.039 0.81 0.49–1.33 0.403
Infliximab** 0.43 0.15–1.27 0.127 0.08 0.03–0.20 0.000 0.28 0.13–0.58 0.001
Established 0.54 0.18–1.67 0.285 0.53 0.29–0.95 0.032 0.61 0.39–0.97 0.038
MTX 0.59 0.13–2.74 0.501 1.06 0.46–2.46 0.884 2.15 1.25–3.70 0.006
DMaRDs pre 0.31 0.12–0.85 0.022 0.62 0.34–1.12 0.112 0.52 0.31–0.89 0.018
.1 indication 1.68 0.45–6.23 0.437 1.48 0.63–3.50 0.368 1.31 0.42–4.08 0.637
Notes: Due to small sample size, models on ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis did not converge. *All patients with psoriasis were placed in stage 
1 for disease severity; **versus adalimumab. Infliximab proved to be a protective predictor of nonadherence for all indications.
Abbreviations:  DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; OR, odds ratio; CI, confidence interval; pre, previous use of DMARDs.
Crohn’s disease
0%
33%
74%
68%
Adalimumab Etanercept Infliximab
63%
69% 72%
89%
59%
0%
74% 69%
88%
75%
100%
64% 67%
73%
78%
65%
Ulcerative colitis Psoriasis Psoriatic arthritis Rheumatoid arthritis Ankylosing
spondylitis
Total
26%
Figure 2 First biologic line: stay on treatment.
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from administrative claims.15 We identified considerable 
variations in the definitions and methodologies of how adher-
ence was measured in the studies, the major issue being the 
lack of agreement in terminology and methodologies for 
measurement of therapy course and outcome, making dif-
ficult a comparison of the results of studies assessing this 
issue. Three key aspects indicate that our results are more 
representative of a real-world scenario than those reported 
in the above studies; ie, the LHU involved covers the nation-
wide distribution, the methods to evaluate the adherence to 
the treatment were standardized, and all indications for each 
drug were evaluated.
In our study we found that the adherence to treatment was 
associated with decreased hospital health care costs. Based on 
our analysis, the annual TNF alpha-inhibitors cost per treated 
patient was the lowest for infliximab across all indications. 
The higher adherence level (.80%) was associated with 
higher pharmacological costs (€14,890 vs €7,453), while 
patients with higher adherence rates had lower nonphar-
macological costs (€988 vs €1,255). In particular, patients 
with lower nonpharmacological costs utilized fewer medi-
cal resources, suggesting a positive effect on quality of life. 
Excluding confounding factors, infliximab proved to be a 
protective predictor of nonadherence for all indications. 
Information on patients’ persistence with biological anti-TNF 
alpha therapies is limited and the effects of persistence on 
the cost of therapy are unknown. In agreement with our data, 
a retrospective study that measured the level of adherence to 
biologic regimens in patients with RA in clinical practice 
showed that patients treated with infliximab + MTX have 
significantly higher persistence compared with those treated 
with adalimumab + MTX or etanercept + MTX. Pharmacy 
costs were higher in patients with .80% persistence, while 
nonpharmacy costs were lower.23
Information from our study appears relevant also beyond 
the Italian setting because it provides valuable informa-
tion that integrates results from studies carried out in other 
countries. Future research should explore further determi-
nants of nonadherence and continue to examine the efficacy 
of implementing various strategies to improve medication 
management in this patient population. Whether different 
routes of administration of anti-TNF alpha agents affect 
adherence to therapy and therapeutic outcomes should also 
be considered. The scientific literature suggests that the 
 likelihood of adherence to IV treatment regimens is higher 
than with the SC routes.36 IV dosing allows continuous dos-
age adjustments to be made, affording flexibility in matching 
patient needs at any given time  during the infusion and help-
ing to optimize overall treatment outcomes.  Nonetheless, this 
question needs to be evaluated qualitatively and quantitatively 
by further research. A limitation of this study was that the 
reasons for nonadherence or discontinuation of treatment 
and the weight of the patients were not available from the 
administrative database.
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